Indirect methods of comparison of the safety of ferric derisomaltose, iron sucrose and ferric carboxymaltose in the treatment of iron deficiency anemia

References

• Avni T, Bieber A, Steinmetz T, et al. Treatment of anemia in inflammatory bowel disease–systematic review and meta-analysis. PLoS One. 2013;8(12):e75540.
   PubMed Web of Science ®Google Scholar
• Bonovas S, Fiorino G, Allocca M, et al. intravenous versus oral iron for the treatment of anemia in inflammatory bowel disease: a systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2016;95(2):e2308.
   PubMed Web of Science ®Google Scholar
• Avni T, Leibovici L, Gafter-Gvili A. Iron supplementation for the treatment of chronic heart failure and iron deficiency: systematic review and meta-analysis. Eur J Heart Fail. 2012;14(4):423–429.
   PubMed Web of Science ®Google Scholar
• O’Lone EL, Hodson EM, Nistor I, et al. Parenteral versus oral iron therapy for adults and children with chronic kidney disease. Cochrane Database Syst Rev. 2019;2:CD007857.
   PubMed Web of Science ®Google Scholar
• Susantitaphong P, Alqahtani F, Jaber BL. Efficacy and safety of intravenous iron therapy for functional iron deficiency anemia in hemodialysis patients: a meta-analysis. Am J Nephrol. 2014;39(2):130–141.
   PubMed Web of Science ®Google Scholar
• Reveiz L, Gyte GM, Cuervo LG, et al. Treatments for iron-deficiency anaemia in pregnancy. Cochrane Database Syst Rev. 2011;2011(10):CD003094.
   Google Scholar
• Chertow GM, Mason PD, Vaage-Nilsen O, et al. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant. 2006;21(2):378–382.
   PubMed Web of Science ®Google Scholar
• Fletes R, Lazarus JM, Gage J, et al. Suspected iron dextran-related adverse drug events in hemodialysis patients. Am J Kidney Dis. 2001;37(4):743–749.
   PubMed Web of Science ®Google Scholar
• Chertow GM, Mason PD, Vaage-Nilsen O, et al. On the relative safety of parenteral iron formulations. Nephrol Dial Transplant. 2004;19(6):1571–1575.
   PubMed Web of Science ®Google Scholar
• Wysowski DK, Swartz L, Borders-Hemphill BV, et al. Use of parenteral iron products and serious anaphylactic-type reactions. Am J Hematol. 2010;85:650–656.
   PubMed Web of Science ®Google Scholar
• Pharmacosmos A/S. A trial comparing the incidence of hypophosphatemia in relation to treatment with iron isomaltoside and ferric carboxymaltose in subjects with iron deficiency anaemia (IDA-04). NCT03238911. [ cited 2019 Aug 22]. Available from: https://clinicaltrials.gov/ct2/show/NCT03238911
   Google Scholar
• Pharmacosmos A/S. A Trial Comparing the Incidence of Hypophosphatemia in Relation to Treatment With Iron Isomaltoside and Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia (IDA-05). NCT03237065. [ cited 2019 Sep 5]. Available from: https://clinicaltrials.gov/ct2/show/NCT03237065
   Google Scholar
• Ehlken B, Nathell L, Gohlke A, et al. Evaluation of the reported rates of severe hypersensitivity reactions associated with ferric carboxymaltose and iron (III) isomaltoside 1000 in europe based on data from eudravigilance and VigiBase™ between 2014 and 2017. Drug Saf. 2019;42(3):463−71.
   PubMed Web of Science ®Google Scholar
• Schaffalitzky de Muckadell P, Strom CC. Comment on ‘evaluation of the reported rates of severe hypersensitivity reactions associated with ferric carboxymaltose and iron(III) isomaltoside 1000 in Europe based on data from eudravigilance and vigibase™ between 2014 and 2017ʹ. Drug Saf. 2019;42(5):689–691.
   PubMed Web of Science ®Google Scholar
• OCEBM Levels of Evidence Working Group. The oxford levels of evidence 2. Oxford Centre for Evidence-Based Medicine. [ cited 2019 Oct 14]. Available from: https://www.cebm.net/index.aspx?o=5653
   Google Scholar
• Burns PB, Rohrich RJ, Chung KC. The levels of evidence and their role in evidence-based medicine. Plast Reconstr Surg. 2011;128(1):305–310.
   PubMed Web of Science ®Google Scholar
• Kalra PA, Bhandari S. Safety of intravenous iron use in chronic kidney disease. Curr Opin Nephrol Hypertens. 2016;25(6):529–535.
   PubMed Web of Science ®Google Scholar
• Adkinson NF, Strauss WE, Macdougall IC, et al. Comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia: A randomized trial. Am J Hematol. 2018;93(5):683−90.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Center for drug evaluation and research. Application number: 203565Orig1s000. Medical Review. [ cited 2019 Oct 1]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203565Orig1s000MedR.pdf
   Google Scholar
• Plummer M. JAGS: a program for analysis of bayesian graphical models using Gibbs sampling. Proceedings of the 3rd International Workshop on Distributed Statistical Computing (DSC 2003), March 20–22, Vienna, Austria. ISSN 1609-395X.
   Google Scholar
• Brooks SP, Gelman A. General methods for monitoring convergence of iterative simulations. J Comput Graph Stat. 1998;7(4):434–455.
   Web of Science ®Google Scholar
• Clopper C, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika. 1934;26(4):404–413.
   Google Scholar
• Gybel-Brask M, Seeberg J, Thomsen LL, et al. Intravenous iron isomaltoside improves hemoglobin concentration and iron stores in female iron-deficient blood donors: a randomized double-blind placebo-controlled clinical trial. Transfusion. 2018;58(4):974–981.
   PubMed Web of Science ®Google Scholar
• Johansson PI, Rasmussen AS, Thomsen LL. Intravenous iron isomaltoside 1000 (Monofer®) reduces postoperative anaemia in preoperatively non-anaemic patients undergoing elective or subacute coronary artery bypass graft, valve replacement or a combination thereof: a randomized double-blind placebo-controlled clinical trial (the PROTECT trial). Vox Sang. 2015;109(3):257–266.
   PubMed Web of Science ®Google Scholar
• Hildebrandt P, Bruun N, Nielsen O. et al. Effects of administration of iron isomaltoside 1000 in patients with chronic heart failure. A pilot study. Transfus Altern Transfus Med. 2010;11(4):131–137.
   Google Scholar
• Birgegård G, Henry D, Glaspy J, et al. A randomized noninferiority trial of intravenous iron isomaltoside versus oral iron sulfate in patients with nonmyeloid malignancies and anemia receiving chemotherapy: the PROFOUND trial. Pharmacotherapy. 2016;36(4):402–414.
   PubMed Web of Science ®Google Scholar
• Wikström B, Bhandari S, Barany P, et al. Iron isomaltoside 1000: a new intravenous iron for treating iron deficiency in chronic kidney disease. J Nephrol. 2011;24(5):589–596.
   PubMed Web of Science ®Google Scholar
• Kalra PA, Bhandari S, Saxena S, et al. A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia. Nephrol Dial Transplant. 2016;31(4):646–655.
   PubMed Web of Science ®Google Scholar
• Bhandari S, Kalra PA, Kothari J, et al. A randomized, open-label trial of iron isomaltoside 1000 (Monofer®) compared with iron sucrose (Venofer®) as maintenance therapy in haemodialysis patients. Nephrol Dial Transplant. 2015;30(9):1577–1589.
   PubMed Web of Science ®Google Scholar
• Pharmacosmos A/S. Iron isomaltoside and iron sucrose for the treatment of iron deficiency anemia in non-dialysis-dependent chronic kidney disease. NCT02940860. [ cited 2019 Oct 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT02940860
   Google Scholar
• Pharmacosmos A/S. An extension trial to assess the safety of re-dosing of iron isomaltoside (Monofer®) (FerWonExt). October 1, 2019 [cited 2019 Sept 5]. Available from: https://clinicaltrials.gov/ct2/show/NCT02962648
   Google Scholar
• Reinisch W, Staun M, Tandon RK, et al. A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1,000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED). Am J Gastroenterol. 2013;108(12):1877–1888.
   PubMed Web of Science ®Google Scholar
• Reinisch W, Altorjay I, Zsigmond F, et al. A 1-year trial of repeated high-dose intravenous iron isomaltoside 1000 to maintain stable hemoglobin levels in inflammatory bowel disease. Scand J Gastroenterol. 2015;50(10):1226–1233.
   PubMed Web of Science ®Google Scholar
• Dahlerup JF, Jacobsen BA, van der Woude J, et al. High-dose fast infusion of parenteral iron isomaltoside is efficacious in inflammatory bowel disease patients with iron-deficiency anaemia without profound changes in phosphate or fibroblast growth factor 23. Scand J Gastroenterol. 2016;51(11):1332–1338.
   PubMed Web of Science ®Google Scholar
• Derman R, Roman E, Modiano MR, et al. A randomized trial of iron isomaltoside versus iron sucrose in patients with iron deficiency anemia. Am J Hematol. 2017;92(3):286–291.
   PubMed Web of Science ®Google Scholar
• Auerbach M, Henry D, Derman RJ, et al. A prospective, multi-center, randomized comparison of iron isomaltoside 1000 versus iron sucrose in patients with iron deficiency anemia; the FERWON-IDA trial. Am J Hematol. 2019;94:1007–1014. Online publication ahead of print.
   PubMed Web of Science ®Google Scholar
• Holm C, Thomsen LL, Norgaard A, et al. Intravenous iron isomaltoside 1000 administered by high single-dose infusions or standard medical care for the treatment of fatigue in women after postpartum haemorrhage: study protocol for a randomised controlled trial. Trials. 2015;16:5.
   PubMed Web of Science ®Google Scholar
• Pharmacosmos A/S. Treatment of women after severe postpartum haemorrhage (PP-02). NCT01895205. [ cited 2019 September 5]. Available from: https://clinicaltrials.gov/ct2/show/NCT01895205
   Google Scholar
• Onken JE, Bregman DB, Harrington RA, et al. Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial. Nephrol Dial Transplant. 2014;29(4):833–842.
   PubMed Web of Science ®Google Scholar
• Onken JE, Bregman DB, Harrington RA, et al. A multicenter, randomized, active-controlled study to investigate the efficacy and safety of intravenous ferric carboxymaltose in patients with iron deficiency anemia. Transfusion. 2014;54(2):306–315.
   PubMed Web of Science ®Google Scholar
• Wolf M, Rubin J, Achebe M, et al. OR13-3 effects of iron isomaltoside versus ferric carboxymaltose on hormonal control of phosphate homeostasis: the PHOSPHARE-IDA04/05 randomized controlled trials. J Endocr Soc. 2019;3(Suppl 1): OR13–3.
   PubMedGoogle Scholar
• Nathell L, Gohlke A, Wohlfeil S. Reported severe hypersensitivity reactions after intravenous iron administration in the European Economic Area (EEA) before and after implementation of risk minimization measures. Drug Saf. 2019. Online publication ahead of print. DOI:10.1007/s40264-019-00868-5
   Web of Science ®Google Scholar
• Weber JCP. Epidemiology of adverse reactions to nonsteroidal anti-inflammatory drugs. In: Rainsford KD, Velo GD, editors. Side-effects of anti-inflammatory drugs, advances in inflammation research. New York: Raven Press; 1984:1–7.
   Google Scholar
• Medical Dictionary for Regulatory Activities. Standardised MedDRA queries. [ cited 2019 October 29]. Available from: https://www.meddra.org/standardised-meddra-queries
   Google Scholar